Filing Details
- Accession Number:
- 0001209191-22-060077
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-06 17:31:47
- Reporting Period:
- 2022-12-02
- Accepted Time:
- 2022-12-06 17:31:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1287098 | Maxcyte Inc. | MXCT | Services-Commercial Physical & Biological Research (8731) | 522210438 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1874572 | M. Thomas Ross | C/O Maxcyte, Inc. 9713 Key West Avenue, Suite 400 Rockville MD 20850 | Evp, Global Sales & Marketing | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-12-02 | 15,000 | $1.08 | 15,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-12-02 | 15,000 | $6.02 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-12-05 | 14,133 | $1.08 | 14,133 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-12-05 | 14,133 | $5.59 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2022-12-02 | 15,000 | $0.00 | 15,000 | $1.08 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2022-12-05 | 14,133 | $0.00 | 14,133 | $1.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 45,734 | 2026-06-13 | No | 4 | M | Direct | |
| 31,601 | 2026-06-13 | No | 4 | M | Direct |
Footnotes
- The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022.
- This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.35 to $5.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- This option is fully vested and exercisable.
Billionaire Hedge Funds
